menu

Investors & Media

Press Releases

View all press releases »
PDF Version

Webcast Alert: Isis Pharmaceuticals, Inc. Discusses Debt Retirement Progress On the Web; Live and Archived Conference Call Notification

July 3, 2002 at 12:00 AM EDT

CARLSBAD, Calif., July 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) discusses debt retirement progress; you are invited to listen to this call which will be broadcast live over the Internet on Wednesday, July 3, at 10 am Eastern Daylight Time. 

    What:     Isis Pharmaceuticals, Inc. Discusses Debt Retirement Progress



    When:     Wednesday, July 3 @ 10 a.m. EDT



    Where:    http://www.firstcallevents.com/service/ajwz361322089gf12.html



    How:      Live over the Internet -- Simply log on to the web at the
              address above.



    Contact:  Karen Lundstedt, 760 603 3880

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The Company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 antisense products in its development pipeline, with two in late-stage development and six in Phase II human clinical trials. Affinitac™ (LY900003/ISIS 3521), an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III human clinical trials for Crohn's disease. Isis has a broad patent estate, as the owner or exclusive licensee of more than 900 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at www.isispharm.com .

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp , and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to isproducers@prnewswire.com.)
SOURCE Isis Pharmaceuticals, Inc.
Web site: http: //www.isispharm.com
CONTACT: Karen Lundstedt of Isis Pharmaceuticals, Inc., +1-760-603-3880
Audio: http: //www.firstcallevents.com/service/ajwz361322089gf12.html